Literature DB >> 12920224

Induced expression of syndecan-1 in the stroma of head and neck squamous cell carcinoma.

Perkins Mukunyadzi1, Kela Liu, Ehab Y Hanna, James Y Suen, Chun-Yang Fan.   

Abstract

Syndecan-1 (CD138), a cell-surface heparan sulfate proteoglycan, is involved in cell-cell, cell-matrix interaction and growth factor binding. Loss of expression of syndecan-1 in tumor cells leads to decreased intercellular cohesion, increased potential for tumor invasiveness, and metastatic spread. Furthermore, induction of syndecan-1 expression in the tumor stroma has been postulated to promote tumor angiogenesis via its binding to growth factors such as basic fibroblast growth factor. Although syndecan-1 expression within tumor cells has been investigated in head and neck squamous cell carcinoma, stromal expression has not been studied in detail. We analyzed 38 cases of head and neck squamous cell carcinoma by immunohistochemical staining for syndecan-1 expression within the stroma. The expression of syndecan-1 within tumor cells of various histologic grades of differentiation, squamous cell carcinoma in situ cells, and benign squamous epithelium was also determined. Variable levels of diminished syndecan-1 expression were noted within the dysplastic cells of 9 of 16 (60%) squamous cell carcinoma in situ lesions and in all 38 (100%) invasive squamous cell carcinoma. In general, higher levels of syndecan-1 expression were observed in the well-differentiated tumors, in contrast to significant reduction of expression seen in poorly differentiated tumors. Syndecan-1 expression was observed within the stroma (in fibroblasts) surrounding infiltrating carcinoma cells in 28 of 38 (74%) cases. The intensity of syndecan-1 staining within the stroma showed generally an inverse correlation with the degree of tumor cell differentiation. Syndecan-1 expression was not detected in the stroma beneath normal squamous epithelium or adjacent to areas of squamous cell carcinoma in situ. We conclude that induced expression of syndecan-1 in the stroma surrounding tumor cells of invasive head and neck squamous cell carcinoma is a frequent event. The increased stromal syndecan-1 expression, coupled with its loss from the surface of carcinoma cells, may contribute to tumor cell invasion and the development of metastases.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12920224     DOI: 10.1097/01.MP.0000081731.17549.53

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  12 in total

Review 1.  Epithelioid sarcoma in a child presenting as a submandibular mass.

Authors:  S Al-Salam; M Al Ashari
Journal:  Afr Health Sci       Date:  2010-12       Impact factor: 0.927

2.  The expression of syndecan-1 is related to the risk of endometrial hyperplasia progressing to endometrial carcinoma.

Authors:  Hyunjin Kim; Dong Soon Choi; Suk-Joon Chang; Jae Ho Han; Churl K Min; Ki-Hong Chang; Hee-Sug Ryu
Journal:  J Gynecol Oncol       Date:  2010-03-31       Impact factor: 4.401

3.  Prognostic significance of syndecan-1 expression in squamous cell carcinoma of the tonsil.

Authors:  Sung Hak Lee; Eun Ji Choi; Min Sik Kim; Jun Wook Park; Youn Soo Lee; Su Young Kim; Chang Suk Kang
Journal:  Int J Clin Oncol       Date:  2013-04-04       Impact factor: 3.402

4.  Membrane glycoproteins associated with breast tumor cell progression identified by a lectin affinity approach.

Authors:  Yanfei Wang; Xiaoping Ao; Huy Vuong; Meghana Konanur; Fred R Miller; Steve Goodison; David M Lubman
Journal:  J Proteome Res       Date:  2008-08-27       Impact factor: 4.466

5.  Proteoglycan-based diversification of disease outcome in head and neck cancer patients identifies NG2/CSPG4 and syndecan-2 as unique relapse and overall survival predicting factors.

Authors:  Anna Farnedi; Silvia Rossi; Nicoletta Bertani; Mariolina Gulli; Enrico Maria Silini; Maria Teresa Mucignat; Tito Poli; Enrico Sesenna; Davide Lanfranco; Lucio Montebugnoli; Elisa Leonardi; Claudio Marchetti; Renato Cocchi; Andrea Ambrosini-Spaltro; Maria Pia Foschini; Roberto Perris
Journal:  BMC Cancer       Date:  2015-05-03       Impact factor: 4.430

Review 6.  Syndecan-1 in Cancer: Implications for Cell Signaling, Differentiation, and Prognostication.

Authors:  Tünde Szatmári; Rita Ötvös; Anders Hjerpe; Katalin Dobra
Journal:  Dis Markers       Date:  2015-09-01       Impact factor: 3.434

7.  Differences in E-Cadherin and Syndecan-1 Expression in Different Types of Ameloblastomas.

Authors:  Ramón G Carreón-Burciaga; Rogelio González-González; Nelly Molina-Frechero; Sandra López-Verdín; Vanesa Pereira-Prado; Ronell Bologna-Molina
Journal:  Anal Cell Pathol (Amst)       Date:  2018-04-23       Impact factor: 2.916

8.  Comparison of Syndecan-1 Immunohistochemical Expression in Lobular and Ductal Breast Carcinoma with Nodal Metastases.

Authors:  Ivana Miše; Majda Vučić
Journal:  Anal Cell Pathol (Amst)       Date:  2018-07-29       Impact factor: 2.916

9.  Aberrant Expression of Syndecan-1 in Cervical Cancers.

Authors:  Katalin Karászi; Renáta Vigh; Miklós Máthé; Alexandra Fullár; Lászlóné Oláh; Tibor Füle; Zoltán Papp; Ilona Kovalszky
Journal:  Pathol Oncol Res       Date:  2020-05-10       Impact factor: 3.201

10.  Clinical implications in the shift of syndecan-1 expression from the cell membrane to the cytoplasm in bladder cancer.

Authors:  Makito Miyake; Adrienne Lawton; Yunfeng Dai; Myron Chang; Lourdes Mengual; Antonio Alcaraz; Steve Goodison; Charles J Rosser
Journal:  BMC Cancer       Date:  2014-02-13       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.